Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alteplase in acute ischemic stroke within 3 hours
NCT00147316Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Apr 2002
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tissue-plasminogen activator in ischemic stroke, sponsored by Mitsubishi Tanabe Pharma. Primary endpoints: Modified Rankin Scale Score of 0-1 at 3 months and Symptomatic Intracranial Hemorrhage at 36 hours. Started Apr 2002; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00147316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00147316.